ATE362487T1 - N-substituierte l-aminosäuren enthaltende peptide,zur prävention der beta-strang assoziation - Google Patents

N-substituierte l-aminosäuren enthaltende peptide,zur prävention der beta-strang assoziation

Info

Publication number
ATE362487T1
ATE362487T1 AT00948175T AT00948175T ATE362487T1 AT E362487 T1 ATE362487 T1 AT E362487T1 AT 00948175 T AT00948175 T AT 00948175T AT 00948175 T AT00948175 T AT 00948175T AT E362487 T1 ATE362487 T1 AT E362487T1
Authority
AT
Austria
Prior art keywords
peptide
beta
substituted
nalpha
strand
Prior art date
Application number
AT00948175T
Other languages
English (en)
Inventor
Kelvin Stott
Original Assignee
Senexis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senexis Ltd filed Critical Senexis Ltd
Application granted granted Critical
Publication of ATE362487T1 publication Critical patent/ATE362487T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT00948175T 1999-07-28 2000-07-28 N-substituierte l-aminosäuren enthaltende peptide,zur prävention der beta-strang assoziation ATE362487T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9917724.8A GB9917724D0 (en) 1999-07-28 1999-07-28 Peptides

Publications (1)

Publication Number Publication Date
ATE362487T1 true ATE362487T1 (de) 2007-06-15

Family

ID=10858096

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00948175T ATE362487T1 (de) 1999-07-28 2000-07-28 N-substituierte l-aminosäuren enthaltende peptide,zur prävention der beta-strang assoziation

Country Status (10)

Country Link
US (1) US7125838B1 (de)
EP (1) EP1203019B1 (de)
JP (1) JP2003505469A (de)
AT (1) ATE362487T1 (de)
AU (1) AU766992B2 (de)
CA (1) CA2378779A1 (de)
DE (1) DE60034888D1 (de)
GB (1) GB9917724D0 (de)
NZ (1) NZ516441A (de)
WO (1) WO2001007473A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1395833B1 (de) 2001-05-31 2013-02-27 Adlyfe, Inc. Verfahren zum erkennen von inkorrekt gefalteten proteinen
US20050026165A1 (en) * 2001-05-31 2005-02-03 Cindy Orser Detection of conformationally altered proteins and prions
DE10230141B4 (de) * 2002-07-04 2004-07-15 Priontype Gmbh Verfahren und Kit zur Anreicherung und zum Nachweis von veränderten Prion-Proteinen (PrPSc)
CA2489754A1 (en) * 2002-07-08 2004-01-15 Applied Research Systems Ars Holding N.V. .beta.-sheet breaking peptides
EP1618129A2 (de) * 2003-04-30 2006-01-25 Applied Research Systems ARS Holding N.V. Inhibitoren von beta-amyloid und deren verwendung
US8372593B2 (en) * 2005-02-15 2013-02-12 Adlyfe, Inc. Method for detecting misfolded proteins and prions
EP2913056A1 (de) * 2006-01-05 2015-09-02 The University of Utah Research Foundation Verfahren und Zusammensetzungen in Zusammenhang mit der Verbesserung von Eigenschaften pharmakologischer Wirkstoffe für das Nervensystem
JP5097206B2 (ja) * 2006-07-28 2012-12-12 エイディーライフ インコーポレイティッド 診断および治療のためのペプチドプローブ
WO2011156003A2 (en) 2010-06-09 2011-12-15 New York University Peptoid and synthetic oligomers, pharmaceutical compositions and methods of using same
JP2014501248A (ja) 2010-12-15 2014-01-20 ニューロアジュヴァンツ，インコーポレイテッド ニューロペプチド類似体、組成物、及び疼痛の治療方法
WO2013054110A2 (en) * 2011-10-10 2013-04-18 University Of Lancaster Compositions for binding to amyloid proteins
WO2021091369A1 (en) * 2019-11-07 2021-05-14 N.V. Nutricia Extensive whey protein hydrolysate with tolerogenic peptides

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854204A (en) 1995-03-14 1998-12-29 Praecis Pharmaceuticals, Inc. Aβ peptides that modulate β-amyloid aggregation
WO1997021728A1 (en) 1995-12-12 1997-06-19 Karolinska Innovations Ab PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
US6034211A (en) * 1996-06-03 2000-03-07 Kelly; Jeffery W. β-sheet nucleating peptidomimetics
DE19725619A1 (de) 1997-06-17 1998-12-24 Fraunhofer Ges Forschung Peptide als Agonisten und/oder Inhibitoren der Amyloidbildung und Zytotoxizität sowie der Verwendung bei Alzheimer'schen Krankheit, beim Typ II Diabetes mellitus und bei spongiformen Encephalopathien

Also Published As

Publication number Publication date
WO2001007473A1 (en) 2001-02-01
US7125838B1 (en) 2006-10-24
AU766992B2 (en) 2003-10-30
EP1203019B1 (de) 2007-05-16
EP1203019A1 (de) 2002-05-08
AU6173700A (en) 2001-02-13
JP2003505469A (ja) 2003-02-12
GB9917724D0 (en) 1999-09-29
DE60034888D1 (de) 2007-06-28
NZ516441A (en) 2003-11-28
CA2378779A1 (en) 2001-02-01

Similar Documents

Publication Publication Date Title
SI1549333T1 (sl) Analogi kompstatina z izboljĺ ano aktivnostjo
ATE362487T1 (de) N-substituierte l-aminosäuren enthaltende peptide,zur prävention der beta-strang assoziation
NZ333609A (en) Peptide inhibitors of the interaction between P35 and MDM2 and the treatment of tumor cells
WO2000002917A3 (en) Compounds and methods for modulating cadherin-mediated functions
SE0002202D0 (sv) New peptides
CY1109631T1 (el) Χρησιμοποιηση πεπτιδιων, τα οποια εχουν παραχθει απο την αα- ή ββ-αλυσιδα του ανθρωπινου ινωδογονου, για τη θεραπεια σοκ
FI961044A0 (fi) Kininogeeni-inhibiittorit
WO2002018443A3 (en) A recombinant monoclonal antibody to phosphotyrosine-containing proteins
ATE355302T1 (de) N-substituierte d-aminosäuren enthaltende peptide,zur prävention der beta-strang assoziation
DE60233558D1 (de) Aminosäurezusammensetzungen zur linderung einer fehlfunktion der leber
DK1079849T3 (da) Anvendelse af HMG-proteiner til fremstilling af lægemidler med cytotoksisk virkning
SE0301431D0 (sv) Novel antimicrobial peptides
DE69607034D1 (de) Pcna bindende substanz
ATE432984T1 (de) Von mage-10 oder mage-8 abgeleitete hla-a2.1- bindende oligopeptide
ATE550345T1 (de) Sfrp, mit sfrp-interagierende peptidmotive sowie verwendungsverfahren
AR026068A1 (es) Peptidos modificados y peptidomimeticos para el uso en inmunoterapia.
DE69812597D1 (de) Peptide zur Inhibition von HPV E7 Proteinen
AU2003288320A1 (en) Peptides binding the phosphatase 2a protein and polynucleotides encoding same
SG170757A1 (en) Polypeptide having esterase activity and recombinant esterase and use thereof
ATE492637T1 (de) An die lck-sh3 und hck-sh3 domäne bindende peptide
WO2004011491A3 (en) Peptidyl-trna hydrolase of enterococcus faecalis
BRPI0216042B8 (pt) polipeptídeo capaz de se ligar a ang-2, vetor de expressão, célula hospedeira, composição farmacêutica, e, uso dos referidos polipeptídeos.
ES1034253U (es) Grapa de fijacion perfeccionada, aplicable en hebillas, adornos y similares.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties